The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

被引：0
|
作者：
Hongping Chen
Da Teng
Bowen Xu
Chunxiao Wang
Hua Wang
Wenjuan Jia
Lei Gong
Haibin Dong
Lin Zhong
Jun Yang
机构：
[1] Qingdao University,School of Medicine
[2] Yuhuangding Hospital,Department of Cardiology
[3] The Fourth School of Clinical Medicine of Qingdao University,undefined
[4] Binzhou Medical University,undefined
来源：
Journal of Cardiovascular Translational Research | 2023年 / 16卷
关键词：
SGLT2 inhibitor; Macrophage; Autophagy; Atherosclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：999 / 1009
页数：10
相关论文
共 50 条
  • [21] Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754)
    Lin, Ronghui
    Hoerr, David C.
    Weaner, Larry E.
    Salter, Rhys
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 (13): : 616 - 623
  • [22] Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans
    Kondo, H.
    Akoumianakis, I.
    Akawi, N.
    Cristina, M.
    Herdman, L.
    Badi, I.
    Kotanidis, C.
    Akbar, N.
    Antonopoulos, A.
    Oikonomou, E.
    Chuaiphichai, S.
    Channon, K.
    Antoniades, C.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3872 - 3872
  • [23] SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice
    Al-Sharea, Annas
    Murphy, Andrew J.
    Huggins, L. A.
    Hu, Y.
    Goldberg, Ira J.
    Nagareddy, Prabhakara R.
    ATHEROSCLEROSIS, 2018, 271 : 166 - 176
  • [24] The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension
    Chowdhury, B.
    Luu, V. Z.
    Luu, A. Z.
    Kabir, M. G.
    Pan, Y.
    Teoh, H.
    Quan, A.
    Mazer, C. D.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2019, 40 : 11 - 11
  • [25] SGLT2 inhibitors and autophagy in diabetes
    Yaribeygi, Habib
    Maleki, Mina
    Atkin, Stephen L.
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    CELL BIOCHEMISTRY AND FUNCTION, 2023, 41 (04) : 392 - 398
  • [26] The SGLT2 inhibitor canagliflozin, but not dapagliflozin or empagliflozin, ameliorates vascular calcification in a mouse model of nephrocalcinosis
    Fernandez, Lucie
    Brunet, Manon
    Buleon, Marie
    Feuillet, Guylene
    Casemayou, Audrey
    Del Bello, Arnaud
    Arefin, Samsul
    Kublickiene, Karolina
    Stenvinkel, Peter
    Schanstra, Joost
    Klein, Julie
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1097 - I1097
  • [27] The Effects of SGLT2 Inhibitor Canagliflozin on Glucagon Secretion in SUR1 Knockout Mice
    Zhang, Tingting
    Han, Dongna
    Meng, Shi
    Li, Ruyue
    Li, Changhong
    DIABETES, 2024, 73
  • [28] The SGLT2 inhibitor canagliflozin, but not dapagliflozin or empagliflozin, ameliorates vascular calcification in a mouse model of nephrocalcinosis
    Fernandez, Lucie
    Brunet, Manon
    Buleon, Marie
    Feuillet, Guylene
    Casemayou, Audrey
    Del Bello, Arnaud
    Arefin, Samsul
    Kublickiene, Karolina
    Stenvinkel, Peter
    Schanstra, Joost
    Klein, Julie
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [29] Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
    Kumiko Shiba
    Kyoichiro Tsuchiya
    Chikara Komiya
    Yasutaka Miyachi
    Kentaro Mori
    Noriko Shimazu
    Shinobu Yamaguchi
    Naomi Ogasawara
    Makoto Katoh
    Michiko Itoh
    Takayoshi Suganami
    Yoshihiro Ogawa
    Scientific Reports, 8
  • [30] Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
    Shiba, Kumiko
    Tsuchiya, Kyoichiro
    Komiya, Chikara
    Miyachi, Yasutaka
    Mori, Kentaro
    Shimazu, Noriko
    Yamaguchi, Shinobu
    Ogasawara, Naomi
    Katoh, Makoto
    Itoh, Michiko
    Suganami, Takayoshi
    Ogawa, Yoshihiro
    SCIENTIFIC REPORTS, 2018, 8
12345